Which factors are used to determine the treatment regimen for acute lymphoblastic leukemia (ALL)?

Updated: Jul 02, 2021
  • Author: Karen Seiter, MD; Chief Editor: Matthew C Foster, MD  more...
  • Print


The treatment regimen for patients with ALL is determined primarily by the Philadelphia chromosome status of the leukemia and the age of the patient. Patients with Philadelphia chromosome–positive (Ph+) ALL receive a tyrosine kinase inhibitor (TKI) in combination with chemotherapy. Patients aged 15-39 years are referred to as "AYA" (adolescent and young adult) and are eligible for more intensive pediatric-style treatment regimens. Patients with Burkitt leukemia/lymphoma are treated with regimens specific for this diagnosis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!